Global Information
회사소개 | 문의 | 비교리스트

요통 : 파이프라인 리뷰

Low Back Pain - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 255955
페이지 정보 영문 130 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


요통 : 파이프라인 리뷰 Low Back Pain - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 130 Pages

요통은 늑골 아래와 다리 사이의 어디에서나 발생할 가능성이 있습니다. 요통의 원인은 혹사, 뒤틀림, 손상, 노화, 관절염, 등뼈 관련 질환 및 암 등이 포함됩니다.

요통(Low Back Pain) 치료제의 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

요통 개요

치료제 개발

  • 파이프라인 제품 개요

요통 : 기업에서 개발중인 치료제

요통 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

요통 : 기업에서 개발중인 제품

요통 치료제 개발에 참여하고 있는 기업

  • Adynxx, Inc.
  • Aestus Therapeutics, Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • Axsome Therapeutics, Inc.
  • Egalet Corporation
  • Frontier Biotechnologies Co., Ltd
  • Gador S.A.
  • Grunenthal GmbH
  • Hisamitsu Pharmaceutical Co., Inc.
  • Immune Pharmaceuticals Inc.
  • Kineta, Inc.
  • MEDRx Co., Ltd.
  • Mesoblast Limited
  • Nektar Therapeutics
  • Orion Oyj
  • Pacira Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Stayble Therapeutics AB

요통 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개요

요통 : 최근의 파이프라인 동향

요통 : 휴지중인 프로젝트

요통 : 개발이 중지된 제품

요통 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 16.06.10

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Low Back Pain, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Low Back Pain - Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2020
  • Low Back Pain - Pipeline by Adynxx Inc, H1 2020
  • Low Back Pain - Pipeline by Allodynic Therapeutics LLC, H1 2020
  • Low Back Pain - Pipeline by Amplicore Inc, H1 2020
  • Low Back Pain - Pipeline by AnGes Inc, H1 2020
  • Low Back Pain - Pipeline by Axsome Therapeutics Inc, H1 2020
  • Low Back Pain - Pipeline by BioRestorative Therapies Inc, H1 2020
  • Low Back Pain - Pipeline by Bol Pharma, H1 2020
  • Low Back Pain - Pipeline by Camurus AB, H1 2020
  • Low Back Pain - Pipeline by Creative Medical Technology Holdings Inc, H1 2020
  • Low Back Pain - Pipeline by Daewon Pharmaceutical Co Ltd, H1 2020
  • Low Back Pain - Pipeline by Frontier Biotechnologies Inc, H1 2020
  • Low Back Pain - Pipeline by Gador SA, H1 2020
  • Low Back Pain - Pipeline by Grunenthal GmbH, H1 2020
  • Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H1 2020
  • Low Back Pain - Pipeline by Imbrium Therapeutics LP, H1 2020
  • Low Back Pain - Pipeline by Immune Pharmaceuticals Inc, H1 2020
  • Low Back Pain - Pipeline by Inspyr Therapeutics Inc, H1 2020
  • Low Back Pain - Pipeline by Intec Pharma Ltd, H1 2020
  • Low Back Pain - Pipeline by MD Biosciences GmbH, H1 2020
  • Low Back Pain - Pipeline by Mesoblast Ltd, H1 2020
  • Low Back Pain - Pipeline by Navipharm Co Ltd, H1 2020
  • Low Back Pain - Pipeline by Persica Pharmaceuticals Ltd, H1 2020
  • Low Back Pain - Pipeline by Pfizer Inc, H1 2020
  • Low Back Pain - Pipeline by Qingdao Chia Tai Haier Pharmaceutical Co Ltd, H1 2020
  • Low Back Pain - Pipeline by Scilex Holding Co, H1 2020
  • Low Back Pain - Pipeline by Stayble Therapeutics AB, H1 2020
  • Low Back Pain - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2020
  • Low Back Pain - Pipeline by Therapix Biosciences Ltd, H1 2020
  • Low Back Pain - Pipeline by WEX Pharmaceuticals Inc, H1 2020
  • Low Back Pain - Pipeline by Xgene Pharmaceutical Inc, H1 2020
  • Low Back Pain - Dormant Projects, H1 2020
  • Low Back Pain - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Low Back Pain - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Low Back Pain, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H1 2020, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 11, 8, 3, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Low Back Pain - Overview
  • Low Back Pain - Therapeutics Development
  • Low Back Pain - Therapeutics Assessment
  • Low Back Pain - Companies Involved in Therapeutics Development
  • Low Back Pain - Drug Profiles
  • Low Back Pain - Dormant Projects
  • Low Back Pain - Discontinued Products
  • Low Back Pain - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q